From: Stereotactic body radiation therapy in the treatment of ovarian cancer
Patient Demographics | Number | Rate |
---|---|---|
Total patients | 35 | Â |
Total lesions | 98 | Â |
Patients with 1 lesion | 17 | 49% |
Patients with 2 lesions | 6 | 17% |
Patients with 3 lesions | 2 | 6% |
Patients with 4 lesions | 3 | 9% |
Patients with ≥5 lesions | 7 | 20% |
Median age at diagnosis (years) | 62.8 (32.7–80.6) |  |
ECOG 0 | 21 | 60% |
ECOG 1 | 11 | 31% |
ECOG 2 | 1 | 3% |
ECOG 3 | 2 | 6% |
ECOG 4 | 0 | 0% |
Histology | ||
 Serous papillary adenocarcinoma | 23 | 66% |
 Mixed | 1 | 3% |
 Clear cell | 1 | 3% |
 Transitional cell | 1 | 3% |
 Granulosa cell | 1 | 3% |
 Endometrioid | 2 | 6% |
 Carcinosarcoma (mixed Mullerian) | 2 | 6% |
 Poorly differentiated / Undifferentiated | 3 | 9% |
 Mucinous | 1 | 3% |
 Positive BRCA 1 | 5 | 14% |
 Positive HRD | 2 | 6% |
 Neoadjuvant chemotherapy | 8 | 23% |
 No neoadjuvant chemotherapy | 27 | 77% |
 Gross residual post-op | 14 | 40% |
 No gross residual post-op | 21 | 60% |
 Median post-chemotherapy CA125 | 18 |  |
 Median pre-SBRT SUV | 5.5 |  |
Staging at Diagnosis | ||
 Stage I | 5 | 14% |
 Stage II | 3 | 9% |
 Stage III | 18 | 51% |
 Stage IV | 9 | 26% |
 Grade 1 | 1 | 3% |
 Grade 2 | 4 | 11% |
 Grade 3 | 26 | 74% |
 Grade NA | 4 | 11% |